Datar Cancer Genetics has signed a $250m contract with US-based diagnostic laboratory company Artemis DNA to offer cancer detection liquid biopsies.
As part of the exclusive agreement, Artemis DNA will provide Datar’s liquid biopsies in the US and Vietnam markets for a period of five years.
Artemis DNA’s contract with Datar covers the latter’s cancer screening and diagnostic portfolio, which includes Trucheck Pragma and Cancertrack.
The non-invasive, blood-based screening test Trucheck Pragma is intended for stomach, colon, lung, pancreas, prostate, breast and ovarian cancers.
Cancertrack has been designed to assess response, resistance and recurrence during cancer management.
Artemis DNA will offer these two solutions as laboratory-developed tests (LDTs) in the US.
Furthermore, the company will provide high-complexity CLIA certified, CAP-accredited testing facilities in Texas and California to Datar.
This will aid in the commercial launch of Datar’s various cancer screening and diagnostic tests.
Datar Cancer Genetics chairman Rajan Datar said: “We are extremely delighted to offer our highly accurate cancer detection technology for the benefit of patients in the US and Vietnam in partnership with Artemis DNA.
“Their marketing strength and experience will enable a seamless roll-out of our innovative, game-changing, life-saving liquid biopsies.”
Datar serves cancer patients as well as suspected cases in the European Union (EU), US, UK, Gulf Cooperation Council (GCC) and India. It has received breakthrough designation from the US Food and Drug Administration (FDA) for its tests for early detection of breast and prostate cancer.
Last March, Datar received CE Mark for its non-invasive liquid biopsy cancer diagnostic test, TruBlood, which serves as a new paradigm to diagnose and manage cancer.